Comparison of the effects of Pramipexole and Gabapentin on the treatment of restless leg syndrome in patients undergoing hemodialysis

Comparison of the effects of Pramipexole and Gabapentin on the treatment of restless leg syndrome in end-stage chronic renal failure patients undergoing hemodialysis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191106045350N1

Enrollment

Registered

2019-11-23

Start date

2018-09-23

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Restless legs syndrome. Restless legs syndrome

Interventions

Intervention 1: Intervention group: Pramipexole 0.18 mg daily for 4 weeks. Intervention 2: Intervention group: Gabapentin 100 mg daily for 4 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with end-stage chronic renal failure (at least 6 months) under permanent hemodialysis Having restless legs syndrome (RLS) based on International RLS Study Group (IRSLSS) diagnostic criteria Moderate to severe RLS based on IRSLSS diagnostic criteria

Exclusion criteria

Exclusion criteria: Pregnancy Iron deficiency anemia Concomitant neurodegenerative diseases such as cerebrovascular accident (CVA) and Parkinson's disease Lyme disease Complications such as nausea, vomiting, and abdominal pain due to medication use

Design outcomes

Primary

Measure	Time frame
Disease severity. Timepoint: Before the study and after 4 weeks of treatment. Method of measurement: Severity scale based on International Restless Legs Syndrome Study Group (IRSLSS) diagnostic criteria.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSepideh Hajian

Qazvin University of Medical Sciences

s.hajian@qums.ac.ir+98 28 3335 3824

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026